131
Participants
Start Date
July 31, 2014
Primary Completion Date
May 31, 2022
Study Completion Date
May 31, 2022
Regorafenib
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Placebo
21 days on and 7 days off
Duke University, Durham
Carolinas Healthcare System, Charlotte
Mayo Clinic - Florida, Jacksonville
H. Lee Moffitt, Tampa
Vanderbilt University, Nashville
Ohio State University, Columbus
Indiana University, Indianapolis
Mayo Clinic - Minnesota, Rochester
Northwestern University, Chicago
Texas Children's Hospital, Houston
Huntsman Cancer Institute, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
Sarcoma Oncology Research Center, Santa Monica
City of Hope National Medical Center, Duarte
Stanford University, Stanford
Oregon Health and Science University, Portland
Seattle Cancer Care Alliance, Seattle
Dana Farber/Partners Cancer Care, Boston
Sarcoma Alliance for Research through Collaboration
OTHER